Studies on lividomycin. I. In vitro antibacterial activities of LVDM against clinical isolates of Mycobacterium tuberculosis.
D002207:Capreomycin / Q000494:pharmacology; D003523:Cycloserine / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000494:pharmacology; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D010303:Paromomycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D012293:Rifampin / Q000494:pharmacology; D013444:Sulfisoxazole / Q000494:pharmacology; D014376:Tuberculosis / Q000188:drug therapy; D014756:Viomycin / Q000494:pharmacology
D002207:Capreomycin; D010303:Paromomycin; D013444:Sulfisoxazole; D004977:Ethambutol; D003523:Cycloserine; D012293:Rifampin; D014756:Viomycin